United Therapeutics Yönetim
Yönetim kriter kontrolleri 2/4
United Therapeutics CEO'su Martine Rothblatt, Jan1996 tarihinde atandı, in görev süresi 28.83 yıldır. in toplam yıllık tazminatı $ 16.96M olup, şirket hissesi ve opsiyonları dahil olmak üzere 8.7% maaş ve 91.3% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.49% ine doğrudan sahiptir ve bu hisseler $ 251.39M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 15.6 yıl ve 22.2 yıldır.
Anahtar bilgiler
Martine Rothblatt
İcra Kurulu Başkanı
US$17.0m
Toplam tazminat
| CEO maaş yüzdesi | 8.7% |
| CEO görev süresi | 28.8yrs |
| CEO sahipliği | 1.5% |
| Yönetim ortalama görev süresi | 15.6yrs |
| Yönetim Kurulu ortalama görev süresi | 22.2yrs |
Son yönetim güncellemeleri
Recent updates
United Therapeutics: One To Believe In Despite Competitive Threats
Nov 14Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 18
Benign Growth For United Therapeutics Corporation (NASDAQ:UTHR) Underpins Its Share Price
Sep 27United Therapeutics: Economics Support Compounding Ability
Aug 20With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jul 26United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Jul 04United Therapeutics Corporation's (NASDAQ:UTHR) Business And Shares Still Trailing The Market
Jun 13United Therapeutics: Exciting Company With A Big Problem
Jun 02We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease
Apr 05United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects
Mar 20Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?
Mar 15Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings
Jan 02United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
Dec 08Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Nov 16United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Sep 04Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Aug 07United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
May 22Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?
Apr 25We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease
Feb 06With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jan 16Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 20United Therapeutics: Ability To Expand Tyvaso To Large IPF Market
Aug 24Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?
Aug 04CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$1b |
| Jun 30 2024 | n/a | n/a | US$1b |
| Mar 31 2024 | n/a | n/a | US$1b |
| Dec 31 2023 | US$17m | US$1m | US$985m |
| Sep 30 2023 | n/a | n/a | US$900m |
| Jun 30 2023 | n/a | n/a | US$872m |
| Mar 31 2023 | n/a | n/a | US$728m |
| Dec 31 2022 | US$5m | US$1m | US$727m |
| Sep 30 2022 | n/a | n/a | US$707m |
| Jun 30 2022 | n/a | n/a | US$631m |
| Mar 31 2022 | n/a | n/a | US$687m |
| Dec 31 2021 | US$4m | US$1m | US$476m |
| Sep 30 2021 | n/a | n/a | US$462m |
| Jun 30 2021 | n/a | n/a | US$471m |
| Mar 31 2021 | n/a | n/a | US$405m |
| Dec 31 2020 | US$5m | US$1m | US$515m |
| Sep 30 2020 | n/a | n/a | US$469m |
| Jun 30 2020 | n/a | n/a | US$430m |
| Mar 31 2020 | n/a | n/a | US$528m |
| Dec 31 2019 | US$46m | US$1m | -US$104m |
| Sep 30 2019 | n/a | n/a | -US$92m |
| Jun 30 2019 | n/a | n/a | -US$118m |
| Mar 31 2019 | n/a | n/a | -US$150m |
| Dec 31 2018 | US$16m | US$1m | US$589m |
| Sep 30 2018 | n/a | n/a | US$543m |
| Jun 30 2018 | n/a | n/a | US$713m |
| Mar 31 2018 | n/a | n/a | US$484m |
| Dec 31 2017 | US$37m | US$1m | US$418m |
Tazminat ve Piyasa: Martine 'nin toplam tazminatı ($USD 16.96M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 12.50M ).
Tazminat ve Kazançlar: Martine 'in maaşı son bir yılda %20'den fazla arttı.
CEO
Martine Rothblatt (69 yo)
28.8yrs
Görev süresi
US$16,958,057
Tazminat
Dr. Martine A. Rothblatt, Ph D., J.D., M.B.A., founded United Therapeutics Corporation in 1996 and has been its Chief Executive Officer since June 26, 2016 and as its Chairman since 1996. Dr. Rothblatt ser...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Founder | 28.8yrs | US$16.96m | 1.49% $ 251.4m | |
| President & COO | 8.4yrs | US$9.81m | 0.0058% $ 971.1k | |
| CFO & Treasurer | 11.8yrs | US$6.05m | 0.018% $ 3.0m | |
| Executive VP | 28.8yrs | US$5.15m | 0.082% $ 13.8m | |
| Head of Investor Relations | no data | Veri yok | Veri yok | |
| Associate Vice President of Human Resources | no data | Veri yok | Veri yok | |
| Senior Vice President of Strategic Operations & Logistics | no data | Veri yok | Veri yok | |
| Executive VP of Technical Operations | 15.6yrs | Veri yok | Veri yok | |
| Executive Vice President of Product Development & Xenotransplantation | no data | Veri yok | Veri yok | |
| Senior VP & Chief Medical Officer | no data | Veri yok | Veri yok |
15.6yrs
Ortalama Görev Süresi
56yo
Ortalama Yaş
Deneyimli Yönetim: UTHR 'un yönetim ekibi deneyimli ve deneyimlidir ( 15.6 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Founder | 28.8yrs | US$16.96m | 1.49% $ 251.4m | |
| Member of the Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 22.8yrs | US$457.60k | 0.027% $ 4.6m | |
| Independent Director & Member of the Scientific Advisory Board | 22.2yrs | US$471.54k | 0.029% $ 4.9m | |
| Independent Director & Member of the Scientific Advisory Board | 22.8yrs | US$456.54k | 0.0039% $ 659.8k | |
| Independent Vice Chairman & Lead Independent Director | 22.1yrs | US$532.60k | 0.0045% $ 754.0k | |
| Independent Director | 21.3yrs | US$481.54k | 0.0082% $ 1.4m | |
| Member of the Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 22.8yrs | US$456.54k | 0.050% $ 8.5m | |
| Member of the Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 9.4yrs | US$488.66k | 0.013% $ 2.1m | |
| Independent Director | 15.6yrs | US$513.66k | 0.039% $ 6.6m |
22.2yrs
Ortalama Görev Süresi
76yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: UTHR 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 22.2 yıldır).